Processa Pharmaceuticals, Inc. (PCSA) stock
PCSANasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.86+0.02 (+1.09%)
Close on Nov 13, 2026Market cap $5.20MP/E –Yield –
Processa Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Processa Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $6.38M. For fiscal 2025 it was $7.81M, up 7.4% from the year before. Over ten years it grew 74.8% a year on average. The highest annual figure on record is $11.49M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.81M | +7.4% |
| FY2024 | Dec 31, 2024 | $7.27M | +25.3% |
| FY2023 | Dec 31, 2023 | $5.80M | -49.5% |
| FY2022 | Dec 31, 2022 | $11.49M | +67.1% |
| FY2021 | Dec 31, 2021 | $6.88M | +116.8% |
| FY2020 | Dec 31, 2020 | $3.17M | +36.7% |
| FY2019 | Dec 31, 2019 | $2.32M | -24.8% |
| FY2018 | Dec 31, 2018 | $3.09M | +220.0% |
| FY2017 | Dec 31, 2017 | $964.16K | -37.3% |
| FY2016 | Dec 31, 2016 | $1.54M | +5155.4% |
| FY2015 | Dec 31, 2015 | $29.25K | -83.6% |
| FY2014 | Dec 31, 2014 | $178.09K | -33.3% |
| FY2013 | Dec 31, 2013 | $267.06K | -40.4% |
| FY2012 | Dec 31, 2012 | $448.03K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.81M | +14.0% |
| Q2 FY2026 | Jun 30, 2026 | $649.88K | -62.0% |
| Q1 FY2026 | Mar 31, 2026 | $1.81M | -20.9% |
| Q4 FY2025 | Dec 31, 2025 | $2.11M | +22.1% |
| Q1 FY2025 | Mar 31, 2025 | $1.59M | +3.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.71M | +29.7% |
| Q3 FY2024 | Sep 30, 2024 | $2.29M | +98.6% |
| Q2 FY2024 | Jun 30, 2024 | $1.73M | +2.5% |
| Q1 FY2024 | Mar 31, 2024 | $1.54M | -5.4% |
| Q4 FY2023 | Dec 31, 2023 | $1.32M | -58.4% |
| Q3 FY2023 | Sep 30, 2023 | $1.15M | -63.3% |
| Q2 FY2023 | Jun 30, 2023 | $1.69M | -46.2% |
| Q1 FY2023 | Mar 31, 2023 | $1.63M | -20.4% |
| Q4 FY2022 | Dec 31, 2022 | $3.17M | +53.3% |
| Q3 FY2022 | Sep 30, 2022 | $3.14M | +82.1% |
| Q2 FY2022 | Jun 30, 2022 | $3.14M | +94.3% |
| Q1 FY2022 | Mar 31, 2022 | $2.04M | +38.5% |
| Q4 FY2021 | Dec 31, 2021 | $2.07M | +21.1% |
| Q3 FY2021 | Sep 30, 2021 | $1.72M | +223.4% |
| Q2 FY2021 | Jun 30, 2021 | $1.61M | +278.1% |
| Q1 FY2021 | Mar 31, 2021 | $1.48M | +194.2% |
| Q4 FY2020 | Dec 31, 2020 | $1.71M | +231.3% |
| Q3 FY2020 | Sep 30, 2020 | $532.59K | -9.0% |
| Q2 FY2020 | Jun 30, 2020 | $427.11K | -41.2% |
| Q1 FY2020 | Mar 31, 2020 | $501.77K | +3.5% |
| Q4 FY2019 | Dec 31, 2019 | $516.40K | -15.0% |
| Q3 FY2019 | Sep 30, 2019 | $584.98K | -4.4% |
| Q2 FY2019 | Jun 30, 2019 | $726.90K | -32.5% |
| Q1 FY2019 | Mar 31, 2019 | $484.75K | -41.0% |
| Q4 FY2018 | Dec 31, 2018 | $607.84K | +217.2% |
| Q3 FY2018 | Sep 30, 2018 | $611.61K | +337.1% |
| Q2 FY2018 | Jun 30, 2018 | $1.08M | -29.6% |
| Q1 FY2018 | Mar 31, 2018 | $821.39K | +142999.0% |
| Q4 FY2017 | Dec 31, 2017 | $191.63K | +3263.7% |
| Q1 FY2017 | Mar 31, 2017 | $139.92K | – |
| Q4 FY2016 | Dec 31, 2016 | $1.53M | – |
| Q3 FY2016 | Sep 30, 2016 | $574 | – |
| Q2 FY2016 | Jun 30, 2016 | $5.70K | – |
See a number that looks wrong?